Frontiers | Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System
![PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/db7fc06d49837a05e1847d9b0f05c8bac76f88c8/3-Figure1-1.png "PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar")
PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar
Frontiers | The emerging neuroprotective roles of exerkines in Alzheimer's disease
Summary of the neuroprotective and deleterious affects of dynorphin A... | Download Scientific Diagram
Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia - ScienceDirect
eNOS-dependent S-nitrosylation of the NF-κB subunit p65 has neuroprotective effects | Cell Death & Disease
Strong Neuroprotection by Inhibition of NF-κB After Neonatal Hypoxia-Ischemia Involves Apoptotic Mechanisms but Is Independent of Cytokines | Stroke
Unraveling the Neuroprotective Effect of Tinospora cordifolia in a Parkinsonian Mouse Model through the Proteomics Approach | ACS Chemical Neuroscience
Neuroprotection for CNS disorders | MedLink Neurology
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection | Molecular Neurodegeneration | Full Text
Neuroprotective effects and mechanisms of ischemic/hypoxic preconditioning on neurological diseases - Liu - 2021 - CNS Neuroscience & Therapeutics - Wiley Online Library
Antioxidants | Special Issue : Role of Natural Antioxidants on Neuroprotection and Neuroinflammation
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies - ScienceDirect
Longshengzhi Capsules Improve Ischemic Stroke Outcomes and Reperfusion Injury via the Promotion of Anti-Inflammatory and Neuroprotective Effects in MCAO/R Rats
Frontiers | What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?
Which Neuroprotective Agents are Ready for Bench to Bedside Translation in the Newborn Infant? - The Journal of Pediatrics
Neuroprotective Mechanism of Lycium barbarum Polysaccharides against Hippocampal-Dependent Spatial Memory Deficits in a Rat Model of Obstructive Sleep Apnea | PLOS ONE
![Glycine Exhibits Neuroprotective Effects in Ischemic Stroke in Rats through the Inhibition of M1 Microglial Polarization via the NF-{kappa}B p65/Hif-1{alpha} Signaling Pathway [IMMUNE REGULATION] – LASID Latin American Society for Immunodeficiencies](https://lasid.org/wp-content/uploads/2019/03/glycine-exhibits-neuroprotective-effects-in-ischemic-stroke-in-rats-through-the-inhibition-of-m1-microglial-polarization-via-the-nf-kappab-p65-hif-1alpha-signaling-pathway-immune-regulation.jpg "Glycine Exhibits Neuroprotective Effects in Ischemic Stroke in Rats through the Inhibition of M1 Microglial Polarization via the NF-{kappa}B p65/Hif-1{alpha} Signaling Pathway [IMMUNE REGULATION] – LASID Latin American Society for Immunodeficiencies")
Glycine Exhibits Neuroprotective Effects in Ischemic Stroke in Rats through the Inhibition of M1 Microglial Polarization via the NF-{kappa}B p65/Hif-1{alpha} Signaling Pathway [IMMUNE REGULATION] – LASID Latin American Society for Immunodeficiencies
![PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/db7fc06d49837a05e1847d9b0f05c8bac76f88c8/5-Figure4-1.png "PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar")
PDF] EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. | Semantic Scholar
Maternal magnesium sulfate fetal neuroprotective effects to the fetus: inhibition of neuronal nitric
Overview of the main mechanisms involved in the neuroprotective effects... | Download Scientific Diagram
Frontiers | Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
